P20. The role of statins in patients with advanced NSCLC harboring KRAS mutation treated with EGFR-TKIs
CELCC 2014 Abstract

P20. The role of statins in patients with advanced NSCLC harboring KRAS mutation treated with EGFR-TKIs

Ondrej Fiala1, Milos Pesek2, Jindrich Finek1, Lucie Benesova3, Marek Minarik3, Zbynek Bortlicek4

1Department of Oncology and Radiotherapy, Faculty Hospital Pilsen, Pilsen, Czech Republic; 2Department of Pneumology and Ftiseology, Faculty Hospital Pilsen, Pilsen, Czech Republic; 3Center for Applied Genomics of Solid Tumours (CEGES), Genomac Research Institut, Prague, Czech Republic; 4Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent novel effective agents approved for the treatment of patients with advanced-stage non-small cell lung cancer (NSCLC). KRAS mutations have been reported as a negative prognostic and predictive factor in patients with NSCLC treated with EGFR-TKIs. Several studies have recently shown that statins can block tumor cell growth, invasion and metastatic potential.

Methods: We analysed clinical data of 67 patients with locally-advanced (IIIB) or metastatic stage (IV) NSCLC harboring KRAS mutation treated with erlotinib or gefitinib. A total of 12 patients were treated with combination of EGFR-TKI and statin and 55 patients were treated with EGFR-TKI alone. Comparison of survival of patients [progression-free survival (PFS) and overall survival (OS)] according to the level of assessed tumor markers was performed using the log-rank test.

Results: The median of PFS and OS for patients treated with EGFR-TKI alone was 1.0 and 5.4 months compared to 2.0 and 14.0 months for patients treated with combination of EGFR-TKI and statin (P=0.037, P=0.181).

Conclusions: The study results proved significant improvement of PFS for patients treated with combination of statin and EGFR-TKI, the difference in OS was not significant.

Keywords: Non-small cell lung cancer (NSCLC); statins; KRAS; erlotinib; gefitinib

doi: 10.3978/j.issn.2218-6751.2014.AB032

Cite this article as: Fiala O, Pesek M, Finek J, Benesova L, Minarik M, Bortlicek Z. The role of statins in patients with advanced NSCLC harboring KRAS mutation treated with EGFR-TKIs. Transl Lung Cancer Res 2014;3(5):AB032. doi: 10.3978/j.issn.2218-6751.2014.AB032

Article Options

Download Citation

Share